Patients with SMA have a variable number of copies of a second gene, called SMN2, which produces a shortened form of the SMN protein with reduced functionality compared to the full-length SMN protein produced by the wildtype SMN1 gene. Here, SMN2 is linked to proximal spinal muscular atrophy.